Start your patients on Otezla
DISCOVER RESULTS IN
PSORIATIC ARTHRITIS^*†

*†The efficacy and safety of Otezla was evaluated in 3 multicenter, randomized, double-blind, placebo-controlled phase 3 trials in adult patients with active psoriatic arthritis (N = 1493). Patients were randomized 1:1:1 to either Otezla 30 mg twice daily, Otezla 20 mg twice daily, or placebo for 24 weeks, after a 5-day titration period. In PALACE 1, Otezla significantly increased ACR20 response (n = 168) at week 16 (primary endpoint) vs placebo (n = 168) (38% vs 19%; P = 0.0001).^1-3

The most common adverse reactions (≥5%) were diarrhea, nausea, and headache.¹